China, Nov. 16 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Andamertinib Monotherapy in EGFRMutant NSCLC with Leptomeningeal Metastases Following EGFRTKI Progression: A Multicenter, OpenLabel, TwoCohort Study (NBHLM01)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600136673

Registration Time: 2026/11/13

Type: Interventional study

Primary Sponsor: Nanjing Brain Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=348696

Published by HT Digital Content Services with permission from Health Daily Digest....